OncoCyte PE Ratio 2014-2024 | OCX
Current and historical p/e ratio for OncoCyte (OCX) from 2014 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. OncoCyte PE ratio as of January 21, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| OncoCyte PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-01-17 | 2.08 | 0.00 | |
| 2024-09-30 | 2.85 | $-2.47 | 0.00 |
| 2024-06-30 | 2.95 | $-2.30 | 0.00 |
| 2024-03-31 | 2.93 | $-3.01 | 0.00 |
| 2023-12-31 | 2.50 | $-1.48 | 0.00 |
| 2023-09-30 | 3.12 | $-1.48 | 0.00 |
| 2023-06-30 | 4.60 | $-2.27 | 0.00 |
| 2023-03-31 | 7.09 | $-2.60 | 0.00 |
| 2022-12-31 | 6.42 | $-5.20 | 0.00 |
| 2022-09-30 | 14.60 | $-13.00 | 0.00 |
| 2022-06-30 | 17.99 | $-14.40 | 0.00 |
| 2022-03-31 | 29.80 | $-15.40 | 0.00 |
| 2021-12-31 | 43.40 | $-14.20 | 0.00 |
| 2021-09-30 | 71.20 | $-8.20 | 0.00 |
| 2021-06-30 | 114.80 | $-7.20 | 0.00 |
| 2021-03-31 | 103.80 | $-7.60 | 0.00 |
| 2020-12-31 | 47.80 | $-9.20 | 0.00 |
| 2020-09-30 | 27.80 | $-10.40 | 0.00 |
| 2020-06-30 | 38.20 | $-10.40 | 0.00 |
| 2020-03-31 | 49.00 | $-9.60 | 0.00 |
| 2019-12-31 | 45.00 | $-8.60 | 0.00 |
| 2019-09-30 | 42.00 | $-7.80 | 0.00 |
| 2019-06-30 | 49.80 | $-7.20 | 0.00 |
| 2019-03-31 | 79.00 | $-7.60 | 0.00 |
| 2018-12-31 | 27.60 | $-8.40 | 0.00 |
| 2018-09-30 | 50.00 | $-8.80 | 0.00 |
| 2018-06-30 | 51.00 | $-11.80 | 0.00 |
| 2018-03-31 | 42.00 | $-12.00 | 0.00 |
| 2017-12-31 | 93.00 | $-12.80 | 0.00 |
| 2017-09-30 | 151.00 | $-12.40 | 0.00 |
| 2017-06-30 | 104.00 | $-10.00 | 0.00 |
| 2017-03-31 | 119.00 | $-9.40 | 0.00 |
| 2016-12-31 | 141.00 | $-8.60 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.035B | $0.002B |
| OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $89.358B | 11.09 |
| Cencora (COR) | United States | $46.783B | 17.59 |
| DiDi Global (DIDIY) | China | $22.844B | 0.00 |
| Natera (NTRA) | United States | $20.907B | 0.00 |
| ICON (ICLR) | Ireland | $16.343B | 14.56 |
| Avantor (AVTR) | United States | $15.048B | 22.56 |
| Revvity (RVTY) | United States | $14.408B | 25.03 |
| BioMerieux (BMXMF) | France | $13.788B | 0.00 |
| Viatris (VTRS) | United States | $13.488B | 4.15 |
| Solventum (SOLV) | United States | $12.699B | 0.00 |
| CochLear (CHEOY) | Australia | $12.341B | 0.00 |
| Medpace Holdings (MEDP) | United States | $10.485B | 29.54 |
| Doximity (DOCS) | United States | $10.029B | 59.03 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $9.551B | 0.00 |
| HealthEquity (HQY) | United States | $8.876B | 44.53 |
| Charles River Laboratories (CRL) | United States | $8.361B | 16.16 |
| Sonic Healthcare (SKHHY) | Australia | $8.244B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $6.136B | 31.28 |
| Bausch + Lomb (BLCO) | Canada | $6.118B | 28.46 |
| Organon (OGN) | United States | $4.054B | 4.09 |
| Sotera Health (SHC) | United States | $3.676B | 19.67 |
| BrightSpring Health Services (BTSG) | United States | $3.230B | 68.70 |
| Alignment Healthcare (ALHC) | United States | $2.795B | 0.00 |
| Concentras Parent (CON) | United States | $2.691B | 0.00 |
| Surgery Partners (SGRY) | United States | $2.566B | 29.26 |
| Premier (PINC) | United States | $2.156B | 11.22 |
| PACS (PACS) | United States | $2.106B | 0.00 |
| Ardent Health Partners (ARDT) | United States | $2.013B | 0.00 |
| GeneDx Holdings (WGS) | United States | $1.909B | 0.00 |
| Progyny (PGNY) | United States | $1.788B | 36.21 |
| GoodRx Holdings (GDRX) | United States | $1.742B | 45.70 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.658B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.565B | 0.00 |
| Agilon Health (AGL) | United States | $1.273B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.189B | 11.63 |
| CareDx (CDNA) | United States | $1.150B | 0.00 |
| Embecta (EMBC) | United States | $1.086B | 7.59 |
| AMN Healthcare Services Inc (AMN) | United States | $0.986B | 6.67 |
| Establishment Labs Holdings (ESTA) | $0.968B | 0.00 | |
| Auna S.A (AUNA) | Luxembourg | $0.624B | 0.00 |
| SBC Medicals (SBC) | United States | $0.518B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.484B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.429B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.426B | 11.15 |
| DocGo (DCGO) | United States | $0.426B | 16.04 |
| Enhabit (EHAB) | United States | $0.402B | 34.74 |
| MultiPlan (MPLN) | United States | $0.260B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.239B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.217B | 0.00 |
| Beauty Health (SKIN) | United States | $0.216B | 0.00 |
| LifeMD (LFMD) | United States | $0.212B | 0.00 |
| Nutex Health (NUTX) | United States | $0.206B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.181B | 0.00 |
| Biodesix (BDSX) | United States | $0.167B | 0.00 |
| So-Young (SY) | China | $0.110B | 18.60 |
| ModivCare (MODV) | United States | $0.093B | 5.03 |
| Ascend Wellness Holdings (AAWH) | United States | $0.085B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.068B | 0.00 |
| NeueHealth (NEUE) | United States | $0.062B | 1.63 |
| Singular Genomics Systems (OMIC) | United States | $0.050B | 0.00 |
| Oncology Institute (TOI) | United States | $0.042B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.032B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.025B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.025B | 0.00 |
| KindlyMD (KDLY) | United States | $0.009B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.008B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.007B | 0.00 | |
| XWELL (XWEL) | United States | $0.007B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| Aclarion (ACON) | United States | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |